GlassScriptPhysician profile
Stephen M Winfield
NPI 1992156970
$3,185.73
in general payments reported to CMS, 2019-2025
21 companies · $1,498 in 2025
The $1,498 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $380 · 2024: $1,308 · 2025: $1,498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,185.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $524.05 | 2023-2025 | Vraylar, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $500.26 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $495.84 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $289.31 | 2023-2025 | Otezla, Repatha, Otezla |
| Pfizer INC. | $253.78 | 2024-2025 | |
| Lilly USA, LLC | $244.21 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $167.06 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $140.84 | 2023-2025 | Rexulti |
| Lundbeck LLC | $128.16 | 2025 | Rexulti |
| Viatris Specialty LLC | $76.45 | 2025 | Yupelri |
| Exact Sciences Corporation | $67.77 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $49.66 | 2024-2025 | Voquezna |
| Axsome Therapeutics, INC. | $47.36 | 2024-2025 | Auvelity |
| Astellas Pharma US INC | $35.79 | 2025 | Veozah |
| Collegium Pharmaceutical, INC. | $34.79 | 2023-2024 | Belbuca |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.13 | 2023 | |
| Dexcom, INC. | $25.69 | 2024 | Dexcom G6 Transmitter |
| Inspire Medical Systems, INC. | $24.67 | 2025 | Inspire |
| Merck Sharp & Dohme LLC | $17.89 | 2025 | Capvaxive, Gardasil 9 |
| E.R. Squibb & Sons, L.L.C. | $15.26 | 2025 | Eliquis |
| Sumitomo Pharma America, INC. | $14.76 | 2024 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Winfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.